A Comprehensive Clinical Review of Radiologic Contrast Media

Introduction to Radiologic Contrast Media

Defining Contrast Media and Their Role in Diagnostic Imaging

Radiologic contrast media, also referred to as contrast agents, are substances administered to patients to temporarily enhance the visibility of internal anatomical structures during diagnostic imaging procedures.[1] Their primary function is to increase the contrast resolution of an image, thereby improving the conspicuity of organs, blood vessels, and pathological tissues relative to their surroundings.[3] This enhancement is critical for accurate diagnosis, allowing clinicians to identify and characterize a wide range of conditions, including tumors, inflammation, vascular abnormalities, and gastrointestinal diseases.[5] It is important to distinguish these agents from dyes that impart a permanent color; contrast media temporarily alter the physical properties of tissues as they interact with the imaging modality and are subsequently absorbed and eliminated by the body.[1] Furthermore, contrast agents used in X-ray-based imaging function by attenuating an external radiation source, which fundamentally differs from radiopharmaceuticals employed in nuclear medicine, which are themselves radioactive and emit radiation.[2]

Fundamental Principles of Image Enhancement

The mechanism by which a contrast agent enhances an image is specific to the imaging modality being used.

- **X-ray Based Modalities (Computed Tomography, Fluoroscopy, Angiography):** In these modalities, image contrast is generated by the differential attenuation (absorption) of X-rays as they pass through the body. Tissues with higher density or higher atomic

number (Z) absorb more X-rays and appear brighter (radiopaque) on the resulting image. Contrast agents for these modalities are formulated with elements that have a high atomic number, primarily iodine ($Z=53$) and barium ($Z=56$), making them highly effective at absorbing X-rays.[7] Iodine is particularly well-suited for this purpose because its innermost electron shell (K-shell) has a binding energy of 33.2 keV, which is very close to the average energy of X-rays used in diagnostic imaging. This proximity maximizes the probability of photoelectric absorption, leading to superior contrast enhancement.[2]

- **Magnetic Resonance Imaging (MRI):** MRI contrast agents operate by altering the magnetic properties of the surrounding tissues, specifically the relaxation times of water protons.[3] The most common agents are gadolinium-based. Gadolinium is a paramagnetic element possessing seven unpaired electrons, the maximum possible for an atom. This unique electronic structure creates a strong local magnetic field that dramatically shortens the spin-lattice relaxation time (T_1) of adjacent water molecules.[11] On T_1-weighted imaging sequences, this accelerated relaxation results in a significantly brighter signal, highlighting the tissues where the contrast agent has accumulated.[1]
- **Ultrasound:** Contrast enhancement in ultrasound is achieved using microbubble agents. These are tiny, gas-filled spheres encapsulated in a supportive shell, which are injected into the bloodstream.[1] The gas within the microbubbles is highly echogenic, meaning it strongly reflects ultrasound waves. This property creates a much brighter signal from within blood vessels compared to the surrounding soft tissues, allowing for detailed assessment of blood flow and organ perfusion.[1]

The selection of a contrast agent is therefore dictated by the physics of the imaging modality. An agent designed for X-ray attenuation, like an iodinated compound, will have no effect on an MRI scan, and a paramagnetic agent like gadolinium is invisible to X-rays. This fundamental dichotomy extends to their safety profiles. Adverse events related to iodinated contrast are often linked to their physicochemical properties, such as high osmolality, which can cause direct physiologic or "chemotoxic" effects.[13] In contrast, the primary safety concerns with gadolinium-based agents, such as nephrogenic systemic fibrosis (NSF) and long-term tissue retention, stem from the toxicological properties of the gadolinium ion itself if it dissociates from its protective carrier molecule.[10] Consequently, a patient's history of an adverse reaction to one class of agent (e.g., an iodinated agent for a CT scan) does not predict a reaction to another class (e.g., a gadolinium-based agent for an MRI). This distinction is clinically vital to prevent the inappropriate withholding of necessary contrast-enhanced examinations based on a misunderstanding of "contrast allergy."

Classification and Properties of Contrast Agents

Contrast agents can be classified based on the imaging modality for which they are designed, their route of administration into the body, and their effect on the final image.

Classification by Imaging Modality

- **X-ray, Computed Tomography (CT), and Fluoroscopy:** These modalities utilize agents that attenuate X-rays. The two primary classes are iodine-based compounds and barium sulfate preparations.[1]
- **Magnetic Resonance Imaging (MRI):** MRI primarily employs gadolinium-based contrast agents (GBCAs) to alter tissue relaxation times.[1] Historically, other agents based on manganese or iron oxides (SPIO and USPIO) were developed, but many have been discontinued due to safety concerns or limited application.[3]
- **Ultrasound:** This modality uses microbubble contrast agents, which are gas-filled microspheres that are highly echogenic.[1]

Classification by Administration Route

- **Oral:** The agent is swallowed to opacify the upper gastrointestinal (GI) tract, including the esophagus, stomach, and small intestine. Barium sulfate is the most common agent for this purpose, though water-soluble iodinated agents may be substituted in certain clinical scenarios.[1]
- **Rectal:** The agent is administered via an enema to opacify the lower GI tract, primarily the colon and rectum. Barium sulfate is the standard agent for this route, commonly known as a barium enema.[1]
- **Intravascular:** The agent is injected directly into the bloodstream, either into a vein (intravenous) or an artery (intra-arterial). This is the most common route for both iodinated and gadolinium-based agents, allowing for visualization of blood vessels, vascular organs (e.g., liver, kidneys), and areas of inflammation or malignancy.[1]
- **Intracavitary/Intrathecal:** The agent is injected into a specific body space. Examples include injection into a joint (arthrography), the uterus and fallopian tubes (hysterosalpingography), or the subarachnoid space surrounding the spinal cord (myelography).[19]

Classification by Radiographic Effect (X-ray/CT)

- **Positive Contrast Agents:** These agents have a higher density (i.e., higher X-ray attenuation) than the surrounding tissues and therefore appear bright or white on radiographic images. This category includes all iodine- and barium-based compounds.[2]
- **Negative Contrast Agents:** These agents have a lower density than surrounding tissues and appear dark or black. Air and carbon dioxide (CO2) are the most common examples. They are frequently used to distend hollow organs and can be administered in conjunction with a positive agent in "double-contrast" studies to provide detailed visualization of the mucosal lining.[2]
- **Neutral Contrast Agents:** These agents are formulated to have a density similar to that of soft tissue. They are used to distend the bowel for CT scans without creating the bright artifact of a positive agent, which could obscure subtle enhancement of the bowel wall. Water is the most commonly used neutral contrast agent.[4]

Agent Class	Sub-types	Primary Modality	Administration Routes	Mechanism of Action
Iodinated	Ionic Monomer (HOCM), Non-ionic Monomer (LOCM), Non-ionic Dimer (IOCM)	CT, Angiography, Fluoroscopy, Radiography	Intravascular, Oral, Rectal, Intracavitary	Attenuation of X-rays via photoelectric absorption by iodine atoms.
Gadolinium-based	Linear (Ionic/Non-ionic), Macrocyclic (Ionic/Non-ionic)	MRI, MRA	Intravascular, Intra-articular	Shortens T_1 relaxation time of adjacent water protons due to paramagnetism.
Barium Sulfate	Suspensions, Pastes,	Fluoroscopy, Radiography,	Oral, Rectal	Attenuation of X-rays due

	Powders	CT		to high atomic number of barium.
Microbubble	Gas-filled microspheres	Ultrasound	Intravascular	High echogenicity (reflection of ultrasound waves) from gas bubbles.
Gas	Air, Carbon Dioxide (CO2)	CT, Fluoroscopy, Angiography	Rectal, Intravascular (CO2)	Lower X-ray attenuation than tissue (negative contrast).
Data compiled from sources:.[1]				

Iodinated Contrast Media (ICM): A Detailed Examination

Chemical Structure and Pharmacology

All contemporary iodinated contrast media (ICM) are derivatives of a tri-iodinated benzene ring.[13] This core structure, with three iodine atoms covalently bonded to it, is responsible for the molecule's ability to attenuate X-rays. The degree of image enhancement is directly proportional to the concentration of iodine delivered to the tissue of interest.[20] The chemical side chains attached to this benzene ring are modified to alter the agent's key physicochemical properties, which in turn determine its safety profile and clinical utility.[9]

Key Properties: Osmolality, Ionicity, and Viscosity

Three primary properties govern the behavior and tolerability of ICM:

- **Ionicity:** This describes whether a contrast molecule dissociates into charged particles (an anion and a cation) when dissolved in a solution like blood.[13] This dissociation effectively doubles the number of particles in the solution for each molecule of the agent, which is a major determinant of osmolality.[13]
- **Osmolality:** This is a measure of the total number of solute particles per kilogram of solvent. Human blood plasma has an osmolality of approximately 290 mOsm/kg H_2O.[9] When a solution with a significantly different osmolality is injected into the bloodstream, it creates an osmotic gradient that can cause fluid shifts and a range of physiologic side effects.[13]
- **Viscosity:** This refers to the thickness or resistance to flow of the contrast solution. Higher viscosity agents require greater injection pressure and can be associated with an increased sensation of warmth or discomfort.[13]

Classification and Evolution of ICM

The development of ICM over the past several decades can be understood as a direct effort to minimize adverse reactions by reducing osmolality.

- **High-Osmolality Contrast Media (HOCM):** These are the first-generation agents, classified as ionic monomers. In solution, each molecule dissociates into two particles, resulting in an extremely high osmolality of 1500–2400 mOsm/kg, which is five to eight times that of blood.[9] This hypertonicity is responsible for a higher incidence of adverse effects, such as pain on injection, sensations of heat, and physiologic disturbances.[13] While their use for intravascular injection has been almost entirely superseded, agents like diatrizoate (Gastrografin) are still employed for oral or rectal administration in gastrointestinal imaging.[9]
- **Low-Osmolality Contrast Media (LOCM):** This class was engineered to reduce the osmolality and improve patient tolerance. The most common type is the **non-ionic monomer**. These molecules have side chains that render them water-soluble without the need for a carboxyl group, so they do not dissociate into ions in solution.[13] This innovation halves the number of particles compared to HOCM, resulting in an osmolality of approximately 600–800 mOsm/kg.[9] While still hyperosmolar relative to blood, this reduction dramatically decreases the rate of adverse reactions.[13] Today, non-ionic LOCM, such as iohexol (Omnipaque), iopamidol (Isovue), and ioversol

(Optiray), are the standard of care for virtually all intravascular applications.[3]

- **Iso-Osmolality Contrast Media (IOCM):** This class represents the most advanced agents in terms of physiologic tolerance. These are **non-ionic dimers**, consisting of two linked tri-iodinated benzene rings. This large, single molecule carries six iodine atoms and does not dissociate, yielding an osmolality of approximately 290 mOsm/kg, which is identical to that of blood.[9] The primary example is iodixanol (Visipaque).[11] While offering the best physiologic profile, these agents are typically more viscous and costly than LOCM.

The clear historical progression from HOCM to LOCM and IOCM was driven by the goal of mitigating risk. The high incidence of physiologic reactions, including severe nausea and vomiting, associated with the extreme hyperosmolality of HOCM necessitated strict patient preparation protocols.[13] The development of non-ionic agents was a direct chemical solution to the problem of dissociation, which was the primary cause of this high osmolality.[13] The resulting improvement in the safety profile of modern LOCM and IOCM has had a profound impact on clinical practice. For example, the significant reduction in emetic events is the direct reason why routine pre-procedural fasting, once a rigid standard, is no longer recommended by major radiological societies for intravascular contrast administration.[23] This pharmaceutical innovation has not only improved patient comfort and safety but has also streamlined departmental workflow and expanded the population of patients who can safely undergo contrast-enhanced imaging.

Gadolinium-Based Contrast Agents (GBCAs): A Detailed Examination

Mechanism of Action in MRI

Gadolinium-based contrast agents (GBCAs) are the cornerstone of contrast-enhanced MRI. Their function relies on the paramagnetic properties of the gadolinium ion (Gd^{3+}).[11] When introduced into the body, GBCAs shorten the T_1 relaxation time of nearby water protons. This acceleration of relaxation leads to a stronger signal on T_1-weighted images, causing tissues with GBCA accumulation to appear bright.[11] However, the free, unchelated Gd^{3+} ion is highly toxic because its ionic radius is similar to that of calcium (Ca^{2+}), allowing it to competitively inhibit numerous calcium-dependent biological processes.[10] To mitigate this toxicity, the Gd^{3+} ion is bound to a large organic molecule known as a chelating ligand. The stability of the bond

between the gadolinium ion and its chelate is the most critical determinant of a GBCA's safety.[10]

Chemical Structure: Linear vs. Macrocyclic Agents

The structure of the chelating ligand is the primary basis for classifying GBCAs and predicting their stability.

- **Linear Agents:** In these agents, the chelating ligand is a flexible, open-chain molecule that wraps around the gadolinium ion. This configuration is less stable and more susceptible to dissociation, which can lead to the release of toxic free Gd^{3+} into the body. This is particularly true in the setting of slow renal clearance.[10]
- **Macrocyclic Agents:** In these agents, the ligand forms a rigid, pre-organized cage-like structure that fully encapsulates the gadolinium ion. This structure provides substantially higher kinetic and thermodynamic stability, making the release of free Gd^{3+} far less likely.[10]

ACR Classification and Nephrogenic Systemic Fibrosis (NSF)

The clinical significance of GBCA stability became profoundly evident with the discovery of Nephrogenic Systemic Fibrosis (NSF), a rare but severe and often fatal fibrosing disorder that occurs almost exclusively in patients with severe renal dysfunction who have been exposed to GBCAs.[5] This led the American College of Radiology (ACR) and other regulatory bodies to classify GBCAs into three groups based on their associated risk of causing NSF.[11]

ACR Group	Associated NSF Risk	Chemical Structure	Example Agents (Generic, Brand Name)
Group I	Highest	Predominantly Linear	Gadodiamide (Omniscan), Gadopentetate dimeglumine

			(Magnevist), Gadoversetamide (OptiMARK)
Group II	Lowest / Negligible	Predominantly Macrocyclic	Gadobutrol (Gadavist), Gadoterate meglumine (Dotarem), Gadoteridol (ProHance), Gadobenate dimeglumine (MultiHance)
Group III	Limited Data	Linear	Gadoxetate disodium (Eovist)
Data compiled from sources:.[5]			

The vast majority of unconfounded NSF cases have been linked to the less stable, linear agents in Group I.[11] In contrast, the macrocyclic agents in Group II are associated with few, if any, cases and are considered to have an extremely low risk of causing NSF, even in patients with severe renal impairment.[11]

This clear hierarchy of safety, directly tied to chemical structure, has fundamentally reshaped clinical practice. The demonstrable safety advantage of Group II macrocyclic agents has made them the universal standard of care, particularly for any patient with known or suspected renal dysfunction. While several GBCAs remain on the market, the clinical reality is a two-tiered system where Group I agents are largely avoided. This paradigm shift has altered the clinical calculus for high-risk patients. The question is no longer whether it is safe to administer gadolinium, but rather, when a contrast-enhanced MRI is clinically essential, a Group II agent must be used. This approach ensures that patients are not denied critical diagnostic information due to outdated fears associated with older, less stable agents, while simultaneously maximizing patient safety.

Barium Sulfate and Other Contrast Agents

Barium Sulfate ($BaSO_4$)

- **Properties:** Barium sulfate is an inert, inorganic salt that is practically insoluble in water and bodily fluids.[28] This insolubility is key to its safety, as soluble barium compounds are highly toxic. Its high atomic number ($Z=56$) makes it extremely radiopaque, providing excellent contrast for GI imaging.[7] Commercial preparations are suspensions of fine $BaSO_4$ particles in water, combined with various additives to control viscosity, improve mucosal coating, and enhance palatability.[2]
- **Applications:** Barium sulfate is the workhorse contrast agent for radiographic and fluoroscopic examinations of the GI tract. It is administered orally for barium swallows (evaluating the pharynx and esophagus), upper GI series (stomach and duodenum), and small bowel follow-through studies.[3] It is administered rectally for barium enemas to evaluate the colon.[2] Diluted barium suspensions are also commonly used as an oral contrast agent for abdominal and pelvic CT scans to opacify the bowel loops.[19]
- **Contraindications:** The primary absolute contraindication for barium sulfate is a known or suspected GI tract perforation. Leakage of barium into the peritoneal or mediastinal space does not get absorbed and can incite a severe inflammatory reaction, leading to granuloma formation and extensive fibrosis (barium peritonitis), which is a serious and often fatal complication.[28] It is also relatively contraindicated in patients with known large bowel obstruction, as water can be reabsorbed from the barium suspension proximal to the obstruction, causing the barium to harden (inspissate) into a concrete-like mass that can be impossible to pass.[28]

Water-Soluble GI Agents

In situations where GI perforation is suspected, water-soluble iodinated contrast agents, such as diatrizoate meglumine/sodium (e.g., Gastrografin), are used as an alternative to barium.[9] If these agents leak from the GI tract, they are readily absorbed from the peritoneal cavity and excreted by the kidneys. However, these agents present their own significant risk. They are hyperosmolar, which can draw large volumes of fluid into the bowel lumen, potentially causing diarrhea and dehydration, especially in infants. More critically, if aspirated into the lungs, these hyperosmolar agents can cause severe, fulminant chemical pneumonitis and pulmonary edema, which is often fatal. Barium, being inert, does not cause this chemical injury if aspirated, though it can cause mechanical obstruction.[28]

Negative and Neutral Contrast Agents

- **Air and Carbon Dioxide (CO2):** These gases are used as negative contrast agents to distend hollow organs, providing a dark background against which the positive contrast-coated mucosa can be seen in sharp relief in double-contrast studies.[2] For CT colonography, CO2 is preferred over room air because it is absorbed much more rapidly from the colon, leading to less post-procedural bloating and discomfort for the patient.[4]
- **Water:** Water can be used as a neutral oral contrast agent for CT of the abdomen. It distends the stomach and proximal small bowel, allowing for excellent evaluation of the bowel wall and mucosal enhancement without the bright artifact from positive contrast agents that might obscure subtle pathology.[4]

Ultrasound Contrast Agents (Microbubbles)

Ultrasound contrast agents consist of microscopic gas-filled bubbles stabilized by a lipid, protein, or polymer shell.[1] When injected intravenously, these microbubbles are confined to the vascular space and are smaller than red blood cells, allowing them to pass through the pulmonary circulation. They are highly echogenic and dramatically increase the signal from blood on ultrasound imaging. This allows for real-time assessment of organ perfusion, characterization of liver and kidney masses by observing their vascular patterns, and evaluation of cardiac chamber abnormalities and function.[1]

Adverse Reactions to Contrast Media: Pathophysiology and Classification

Adverse reactions to contrast media are broadly categorized based on their underlying mechanism, timing of onset, and clinical severity.

Mechanisms of Reactions

- **Allergic-Like (Idiosyncratic/Anaphylactoid) Reactions:** These reactions are unpredictable, are not dependent on the dose administered, and can occur even with a minute amount of contrast. They clinically mimic true IgE-mediated allergic reactions (anaphylaxis), presenting with symptoms like urticaria (hives), angioedema, bronchospasm, and hypotension.[22] While the presentation is similar, the underlying mechanism for most of these events is thought to be a direct, non-immune-mediated release of histamine and other vasoactive mediators from mast cells and basophils, hence the term "anaphylactoid".[13] However, accumulating evidence, including the presence of tryptase and positive skin tests in some patients, suggests that a subset of these reactions may represent true, IgE-mediated allergies.[34]
- **Physiologic (Non-idiosyncratic/Chemotoxic) Reactions:** These reactions are directly related to the physicochemical properties of the contrast agent, primarily its osmolality, ionicity, and viscosity. They are generally dose- and concentration-dependent.[13] Common manifestations include sensations of warmth or heat, a metallic taste in the mouth, nausea, vomiting, and vasovagal responses (transient hypotension and bradycardia).[13] The widespread adoption of low- and iso-osmolar contrast media has dramatically reduced the frequency and severity of these physiologic reactions.[13]

Timing and Onset

- **Acute Reactions:** By definition, these reactions occur within one hour of contrast administration. The vast majority manifest rapidly, typically within the first 5 to 20 minutes post-injection.[13] These are the events that require immediate recognition and management within the imaging department.
- **Delayed Reactions:** These reactions appear between one hour and one week after contrast administration.[20] They are actually more common than acute reactions but are often underreported and misdiagnosed because the patient is no longer under direct medical supervision.[35] The most frequent presentation is a self-limited, pruritic maculopapular skin rash, which is thought to be a T-cell-mediated type IV hypersensitivity reaction.[20]

Severity Grading (for Acute Reactions)

Acute reactions are typically stratified into three levels of severity to guide management:

- **Mild:** Characterized by self-limiting symptoms that generally do not progress and often require no treatment other than observation. Examples include limited urticaria

or pruritus, transient nausea, and mild flushing.[32]

- **Moderate:** Symptoms are more pronounced and typically require medical intervention. Examples include diffuse urticaria, mild bronchospasm or wheezing, facial or laryngeal edema without respiratory distress, and vasovagal reactions requiring treatment.[32]
- **Severe:** These are life-threatening events that require immediate and aggressive emergency treatment. Manifestations include severe respiratory distress from laryngeal edema or bronchospasm, profound hypotension or shock, significant cardiac arrhythmias, convulsions, or cardiac arrest.[32] Fortunately, with modern contrast agents, severe reactions are rare, occurring in approximately 0.04% of intravenous administrations.[9]

Specific Complications: Extravasation

Extravasation is the leakage of intravenously administered contrast media from the vein into the surrounding subcutaneous soft tissues.[13] This complication is more common with the use of automated power injectors for CT, which deliver contrast at high flow rates and pressures.[13] Small-volume extravasations typically result in localized pain, swelling, and erythema, which resolve with conservative management such as limb elevation and the application of cold or warm compresses.[13] However, large-volume extravasations (e.g., >50 mL) can be a serious event, as the hyperosmolar contrast agent can cause significant tissue damage, skin ulceration, and, in severe cases, compartment syndrome—a surgical emergency requiring fasciotomy to prevent permanent muscle and nerve damage.[13]

Prevention and Management of Acute Adverse Reactions

Patient Screening and Risk Factor Identification

While most adverse reactions are unpredictable, certain patient factors are known to increase the risk. Thorough patient screening is the first step in prevention.

- **Previous Contrast Reaction:** A history of a prior allergic-like reaction to the same class of contrast media is the single most significant risk factor, increasing the

likelihood of a subsequent reaction by four to six times.[13] It is crucial to document the specific agent and the nature of the reaction.

- **Asthma:** A history of asthma, particularly if poorly controlled, increases the risk of an allergic-like reaction by five to ten times.[13]
- **Other Allergies:** A history of multiple or severe allergies to unrelated substances (atopy) also confers an increased risk, though to a lesser degree than a prior contrast reaction or asthma.[42]
- **Common Misconceptions:** It is a widely debunked myth that an allergy to shellfish or topical iodine (e.g., Betadine) specifically predisposes a patient to a reaction to iodinated contrast media. These allergies carry no more risk than any other allergy and are not a contraindication.[9]
- **Medications:** Patients taking beta-blockers are at increased risk for more severe and treatment-refractory anaphylactoid reactions. This is because beta-blockade can blunt the therapeutic effects of epinephrine, the primary treatment for severe reactions.[13]

Premedication Protocols for High-Risk Patients

For patients identified as high-risk, particularly those with a previous mild or moderate allergic-like reaction, a prophylactic premedication regimen is recommended. While these regimens reduce the incidence of breakthrough reactions, they do not eliminate the risk entirely.[22]

- **Standard 13-Hour Oral Regimen:** This is the most widely accepted protocol, recommended by the ACR. It consists of prednisone 50 mg taken orally at 13 hours, 7 hours, and 1 hour before contrast administration, combined with diphenhydramine 50 mg orally one hour before the procedure.[44]
- **Alternative Oral Regimen:** An alternative involves methylprednisolone 32 mg orally at 12 hours and 2 hours before contrast administration, often with the addition of an antihistamine one hour prior.[45]
- **Accelerated Intravenous (IV) Regimen:** In urgent or emergency situations where a 12- or 13-hour oral regimen is not feasible, an accelerated IV protocol can be used. This may involve administering an IV corticosteroid (e.g., hydrocortisone 200 mg or methylprednisolone 40 mg) every 4 hours until the scan, along with IV diphenhydramine 50 mg one hour before.[45]

Stepwise Management of Acute Reactions

Prompt recognition and a systematic approach are critical to managing acute reactions effectively. All imaging departments must be equipped with a well-stocked emergency kit or "crash cart" and have staff trained in its use.

Severity	Signs/Symptoms	First-line Actions & Management
Mild	Limited urticaria/pruritus, cutaneous edema, nasal congestion, transient nausea/vomiting.	- Stop contrast injection. - Provide reassurance and observe patient. - Treatment is often not needed. - If symptomatic, consider Diphenhydramine 25-50 mg PO.
Moderate	Diffuse urticaria/pruritus, facial/laryngeal edema (no dyspnea), wheezing/bronchospasm, vasovagal reaction responsive to treatment.	- Stop contrast injection. - Call for medical assistance. - Preserve IV access and monitor vital signs. - **For urticaria:** Diphenhydramine 25-50 mg IV/IM. - **For bronchospasm:** Administer Beta-agonist inhaler (e.g., Albuterol) 2 puffs. Administer Oxygen 6-10 L/min via mask. - **For vasovagal reaction:** Elevate legs, administer IV fluids (0.9% Normal Saline).
Severe	Severe bronchospasm or laryngeal edema with dyspnea/stridor, profound hypotension/shock, loss of consciousness,	- **ACTIVATE EMERGENCY RESPONSE (e.g., Code Blue, 911).** - **Administer EPINEPHRINE IM IMMEDIATELY** (0.3-0.5 mg of 1:1,000 solution)

	cardiac arrhythmia/arrest.	into the anterolateral thigh. Repeat every 5-15 minutes as needed. - Administer high-flow Oxygen 6-10 L/min via mask. - Secure airway if compromised. - For hypotension/shock, elevate legs and give rapid IV fluid bolus (1 L Normal Saline). - Adjunctive therapies (administer after epinephrine): IV Diphenhydramine, IV corticosteroids (e.g., Hydrocortisone), H2-blockers.
Data compiled from sources:.[32]		

Anaphylaxis is a treatable condition, but delays in management can be fatal. The single most critical action in a severe reaction is the prompt administration of intramuscular epinephrine.[33] Despite this, studies have shown a significant "knowledge-to-practice" gap, where medical personnel may hesitate or use an incorrect dose or route of administration under the stress of an emergency.[33] This highlights that the greatest risk to a patient is not the reaction itself, but a delayed or incorrect response from the healthcare team. To mitigate this human-factors problem, best practices now emphasize systemic readiness over mere theoretical knowledge. This includes regular, hands-on simulation training for all staff, the use of pre-filled epinephrine autoinjectors to minimize dosing errors, and the placement of clear, simple visual aids and algorithms in all scanning suites.[33] The focus must be on creating a system that ensures a rapid, correct response every time.

Renal Considerations and Complications

Post-Contrast Acute Kidney Injury (PC-AKI): Redefining Renal Risk

The relationship between iodinated contrast media and renal dysfunction has been a subject of intense study and evolving understanding.

- **Historical Paradigm (Contrast-Induced Nephropathy):** For decades, the prevailing concept was "Contrast-Induced Nephropathy" (CIN), later termed Contrast-Induced Acute Kidney Injury (CI-AKI). It was defined by a specific rise in serum creatinine (e.g., an increase of >25% or >0.5 mg/dL) within 48 to 72 hours following contrast administration, with the explicit assumption that the contrast agent was the cause.[41]
- **Modern Paradigm (Post-Contrast Acute Kidney Injury):** Over the last decade, a wealth of evidence from large-scale, controlled studies has demonstrated that the true risk of CI-AKI from modern intravenous contrast media was substantially overstated.[50] These studies revealed that in many patient populations, particularly those who are hospitalized or have multiple comorbidities, the incidence of acute kidney injury is similar whether they receive IV contrast or not. This indicates that many cases of renal dysfunction previously attributed to contrast were, in fact, coincidental events related to the patient's underlying illness.[51]
- **New Terminology:** To reflect this new understanding, a change in terminology has been widely adopted. The terms **Post-Contrast Acute Kidney Injury (PC-AKI)** or **Contrast-Associated AKI (CA-AKI)** are now preferred.[50] These terms are descriptive, denoting an episode of AKI that occurs in temporal proximity to contrast administration, but they do not presume a causal link. The term CI-AKI is now reserved for the specific subset of cases where a causal relationship can be confidently established, which is often difficult in a complex clinical setting.[51]

This shift in terminology from "induced" to "associated" represents a fundamental change in both clinical practice and medical-legal responsibility. Clinically, it supports the judicious use of contrast-enhanced studies in patients with mild to moderate renal impairment, recognizing that the risk of a missed or delayed diagnosis often far outweighs the minimal, if any, risk of true CI-AKI.[27] It reframes an increase in creatinine after a scan not as an automatic iatrogenic complication, but as a potential manifestation of the patient's underlying pathophysiology, demanding a more nuanced clinical assessment.

Risk Stratification for PC-AKI

The only consistently identified independent risk factor for developing PC-AKI is pre-existing severe renal impairment.[48] Risk stratification is therefore based on the patient's estimated glomerular filtration rate ($eGFR$).

- **eGFR Thresholds for Intravenous (IV) Contrast:**
  - **$eGFR > 45 \text{ mL/min/1.73 m}^2$**: Patients are not considered to be at risk. No special precautions are necessary.[54]
  - **$eGFR 30–44 \text{ mL/min/1.73 m}^2$**: The risk of PC-AKI is very low to nonexistent. Prophylactic measures like IV hydration are generally not recommended but may be considered on a case-by-case basis at the clinician's discretion for patients with multiple comorbidities.[51]
  - **$eGFR < 30 \text{ mL/min/1.73 m}^2$ (and not on dialysis)**: This is the at-risk group. If a contrast-enhanced study is deemed necessary, prophylaxis with intravenous isotonic saline is indicated to reduce risk.[42]
- **Intra-arterial (IA) Contrast:** The risk of PC-AKI is considered higher with IA administration, particularly for procedures involving "first-pass" renal exposure where the contrast is injected directly into the aorta above the renal arteries (e.g., renal angiography).[49] This is due to the higher concentration of contrast reaching the kidneys and the additional risk of atheroembolism from catheter manipulation. For these procedures, a more conservative eGFR threshold (e.g., <45 or $<60 \text{ mL/min/1.73 m}^2$) may be used to trigger prophylactic measures.[48]

Guidelines for Contrast Administration in Patients with Acute Kidney Injury (AKI)

Patients with established, active AKI are considered a high-risk group for further renal injury from any nephrotoxic insult, including potentially from ICM.[27] The decision to administer contrast must be based on a careful risk-benefit analysis. If the diagnostic information is critical and cannot be obtained by other means (e.g., non-contrast CT, MRI, ultrasound), contrast may be administered. In such cases, prophylactic IV hydration with isotonic saline is recommended.[51]

Nephrogenic Systemic Fibrosis (NSF)

NSF is a rare but devastating fibrosing disease strongly linked to the administration of GBCAs in patients with severe renal dysfunction.[10]

- **Risk Factors:** The highest-risk patients are those with an $eGFR < 30 \text{ mL/min/1.73 m}^2$, those on any form of dialysis, and those with AKI.[27]
- **Pathophysiology:** The disease is characterized by widespread fibrosis of the skin, joints, and internal organs, leading to painful skin thickening, joint contractures, and

potentially fatal organ dysfunction.[25]

- **Agent-Specific Risk:** The risk is almost exclusively associated with the older, less stable, linear GBCAs (ACR Group I). The risk with modern macrocyclic GBCAs (ACR Group II) is considered extremely low to negligible, making them the agents of choice if a GBCA is required in a high-risk patient.[11]

Contrast Administration in Patients on Dialysis

- **Iodinated Contrast:** For anuric patients on a stable chronic dialysis regimen, there is no risk of further damage to their non-functioning kidneys. Therefore, ICM can be administered safely.[60] The main theoretical concerns are volume overload from the osmotic load of the contrast and the potential to hasten the loss of any residual renal function in oliguric patients.[60] However, with modern LOCM/IOCM, these risks are minimal. Prophylactic or urgent dialysis immediately following contrast administration has been shown to be unnecessary and does not reduce complications. Patients should simply adhere to their regular dialysis schedule.[41]
- **Gadolinium-Based Contrast:** Patients on dialysis represent the highest-risk group for NSF. If a GBCA-enhanced MRI is clinically unavoidable:
  1. Only a Group II (macrocyclic) agent must be used.[26]
  2. The lowest diagnostic dose should be administered.
  3. While the benefit is not definitively proven, it is recommended to perform hemodialysis as soon as is practical after the scan (ideally within 24 hours) to help clear the circulating agent and theoretically reduce the risk of NSF.[5] It should be noted that peritoneal dialysis is not effective at removing GBCAs and does not reduce the risk.[5]

Special Populations and Drug Interactions

Contrast Media in Pregnancy and Lactation

The use of contrast media in pregnant or lactating patients requires a careful evaluation of the potential risks to the fetus or infant versus the diagnostic benefits for the mother.

- **Pregnancy:**
  - **General Principle:** A contrast-enhanced study should only be performed during

pregnancy if the information is essential for the health of the mother or fetus and cannot be obtained through a non-contrast study or an alternative modality like ultrasound.[61]

- **Iodinated Contrast Media (ICM):** ICM is known to cross the placenta and enter the fetal circulation. While no teratogenic effects have been demonstrated in humans, there is a small, theoretical risk of inducing transient hypothyroidism in the neonate due to the iodine load. If ICM is required, a non-ionic agent is preferred, and it may be advisable to check the neonate's thyroid function after birth.[40]
- **Gadolinium-Based Contrast Agents (GBCAs):** GBCAs also cross the placenta and are excreted by the fetal kidneys into the amniotic fluid. The agent is then swallowed by the fetus and re-circulated, leading to prolonged exposure. Due to concerns that the unstable fetal environment could promote dissociation of the toxic gadolinium ion, GBCAs are generally avoided during pregnancy.[61] Retrospective studies have suggested a possible association between in-utero GBCA exposure and a slightly increased risk of stillbirth and neonatal death, as well as rheumatological and inflammatory skin conditions in childhood.[62] Therefore, GBCAs should only be used in pregnancy when the diagnostic benefit is deemed to unequivocally outweigh these potential risks.[58]

- **Lactation (Breastfeeding):**
  - The amount of both ICM and GBCAs excreted into breast milk is extremely small—less than 0.04% of the administered maternal dose.[61] Of this tiny amount, only a very small fraction (e.g., <2% for ICM) is absorbed from the infant's GI tract.[63] The resulting systemic dose to the infant is negligible.
  - Based on this data, major radiological bodies, including the ACR and the European Society of Urogenital Radiology (ESUR), have concluded that it is safe for a mother to continue breastfeeding without interruption after receiving either ICM or GBCAs.[40] The historical advice to "pump and dump" breast milk for 24–48 hours is outdated and no longer recommended.[21]

Interaction with Metformin

The concern regarding metformin and contrast media is not a direct drug interaction but rather the risk of a rare but life-threatening condition called Metformin-Associated Lactic Acidosis (MALA).[65] Metformin is cleared by the kidneys; if a patient develops PC-AKI after receiving contrast, metformin levels could rise to toxic concentrations, precipitating MALA.[65] Current guidelines are therefore stratified based on the patient's renal function, which determines their risk of developing PC-AKI.

Patient's Renal Function	IV Contrast Procedure Recommendation	Intra-arterial (First-Pass Renal) Procedure Recommendation
$eGFR \geq 30 \text{ mL/min/1.73 m}^2$	**Continue Metformin.** No need to discontinue medication. The risk of PC-AKI is negligible.	**Continue Metformin** (if $eGFR \geq 45$). Some guidelines are more cautious and may recommend holding if $eGFR < 60$.
$eGFR < 30 \text{ mL/min/1.73 m}^2$	**Hold Metformin.** Withhold at the time of the procedure and for 48 hours after. Re-evaluate renal function before restarting.	**Hold Metformin.** Withhold at the time of the procedure and for 48 hours after. Re-evaluate renal function before restarting.
Known Acute Kidney Injury (AKI)	**Hold Metformin.** Withhold at the time of the procedure and for 48 hours after. Re-evaluate renal function before restarting.	**Hold Metformin.** Withhold at the time of the procedure and for 48 hours after. Re-evaluate renal function before restarting.
Data compiled from sources:.[23]		

Interactions with Other Medications

- **Nephrotoxic Medications:** The concurrent use of drugs that can be harmful to the kidneys, such as non-steroidal anti-inflammatory drugs (NSAIDs), aminoglycoside antibiotics, and certain diuretics, may increase a patient's overall risk for developing AKI. While not an absolute contraindication to contrast administration, the decision to temporarily withhold these medications should be made in consultation with the referring physician, weighing the risks and benefits.[43]
- **Beta-blockers:** As previously mentioned, patients on beta-blockers do not have a

higher risk of having a reaction, but if a severe anaphylactoid reaction does occur, it may be more profound and less responsive to standard treatment with epinephrine.[13] This information should be noted during the pre-procedure safety check.

Thyroid-Related Complications of Iodinated Contrast

The substantial iodine load delivered by an injection of ICM can affect thyroid function.

- **Contrast-Induced Hyperthyroidism:** Known as the Jod-Basedow effect, this can be triggered in patients with underlying autonomous thyroid function, such as those with a multinodular goiter or untreated Graves' disease. For this reason, active, untreated hyperthyroidism is a relative contraindication to ICM administration.[9]
- **Contrast-Induced Hypothyroidism:** A transient suppression of thyroid hormone production (the Wolff-Chaikoff effect) can also occur. This is of greater concern in neonates and young infants, whose neurological development is dependent on normal thyroid function.

Procedural Guidelines and Modality-Specific Considerations

Fasting Guidelines: ACR vs. ASA and Current Recommendations

- **Historical Context:** The practice of requiring patients to fast for several hours before receiving intravascular contrast media originated in the era of HOCM. These agents caused a high incidence of nausea and vomiting, and fasting was instituted to reduce gastric volume and theoretically lower the risk of aspiration pneumonia should vomiting occur.[24]
- **Current Evidence and ACR Guidelines:** Modern LOCM, IOCM, and GBCAs are associated with a very low incidence of severe vomiting.[23] Numerous studies and large meta-analyses have failed to show any preventive effect of fasting on the rates of nausea, vomiting, or aspiration.[3] Furthermore, prolonged fasting can cause significant patient discomfort, dehydration, and a risk of hypoglycemia, particularly in diabetic patients.[23] Consequently, the American College of Radiology (ACR) and other major radiological societies explicitly state that **routine fasting of either solids or**

liquids is not required prior to the administration of intravascular contrast media.[23]

- **ASA Guidelines:** The American Society of Anesthesiologists (ASA) publishes strict fasting guidelines (e.g., no clear liquids for 2 hours, no light meal for 6 hours) for patients undergoing procedures that require sedation or general anesthesia.[68]
- **Clarification:** There is no conflict between these guidelines, as they apply to different clinical scenarios. The ASA guidelines are for preventing aspiration during anesthesia. For a routine diagnostic CT or MRI scan performed on an awake and alert patient without sedation, the ACR guidelines apply, and no fasting is necessary.[23] If the radiological procedure itself requires sedation (e.g., some interventional procedures or scans on pediatric or claustrophobic patients), then the ASA guidelines must be followed.

Risk of Aspiration with Oral Contrast

The risk of aspirating oral contrast is a significant concern, especially in patients with impaired swallowing, altered mental status, or conditions like bowel obstruction that predispose them to vomiting.[70] The clinical consequence of aspiration depends critically on the type of contrast agent used.

- **Barium Aspiration:** Barium sulfate is biologically inert. If aspirated, it can cause mechanical obstruction of the airways but does not typically incite a significant inflammatory response.[28]
- Water-Soluble Contrast Aspiration: Hyperosmolar water-soluble agents (e.g., Gastrografin) are extremely dangerous if aspirated. Their high osmolality draws a massive influx of fluid into the alveoli, leading to severe chemical pneumonitis and life-threatening pulmonary edema.28
  This creates a clinical dilemma: for suspected perforation, water-soluble agents are preferred, but if the patient is also at high risk of aspiration, barium may be the safer choice for the lungs.28

Specifics for Computed Tomography (CT)

- **Contrast:** Primarily uses iodinated contrast media administered intravenously, orally, or rectally.[15]
- **IV Administration:** To achieve optimal opacification of arteries for CT angiography (CTA), a compact bolus of contrast is required. This is achieved by using a power injector to deliver a set volume of contrast at a high flow rate (e.g., 3–6 mL/s) through a large-bore peripheral IV (typically 20-gauge or larger).[9]

- **Scan Timing:** The timing of the scan acquisition is precisely synchronized with the arrival of the contrast bolus in the vessel of interest, often using automated bolus-tracking software.[73]

Specifics for Magnetic Resonance Imaging (MRI) and Angiography (MRA)

- **Contrast:** Primarily uses GBCAs.[74]
- **IV Administration:** GBCAs are injected intravenously, often as a manual bolus or via a power injector, typically at slower rates than for CT.[75]
- **MRA:** Magnetic resonance angiography can be performed either with or without contrast. Contrast-enhanced MRA (CE-MRA) uses an intravenous bolus of a GBCA to generate bright-blood images of the vascular system.[11] Non-contrast MRA techniques, such as Time-of-Flight (TOF), rely on flow-related phenomena and are essential alternatives for patients with contraindications to GBCAs.[77]

Specifics for Conventional Angiography and Interventional Radiology

These procedures involve the use of fluoroscopy (real-time X-ray imaging) to guide catheters within the body.

- **Contrast:** Uses iodinated contrast media.[16] For patients with severe renal failure or a history of anaphylaxis to ICM, carbon dioxide gas can be used as an alternative negative contrast agent for imaging vessels below the diaphragm.[4]
- **Administration:** Unlike CTA where contrast is given systemically via a peripheral vein, in conventional angiography the contrast is injected directly into the artery or vein of interest through a selectively placed catheter.[38] This allows for targeted, high-resolution imaging of a specific vascular territory.
- **Volume and Rate:** Contrast is typically injected in smaller, forceful boluses ("puffs") to opacify the target vessel during image acquisition. While individual injection volumes are small, the cumulative dose over a long, complex interventional procedure can be substantial.[80]

Feature	CT Angiography (CTA)	Conventional

		Angiography
Invasiveness	Minimally invasive; requires only peripheral IV access.	Invasive; requires arterial or venous puncture and catheterization.
Contrast Agent	Iodinated Contrast Medium (LOCM/IOCM).	Iodinated Contrast Medium (LOCM/IOCM); CO_2 as an alternative.
Administration Route	Intravenous (systemic delivery).	Intra-arterial or Intravenous (selective delivery via catheter).
Typical Volume	Larger bolus (e.g., 70-150 mL).	Smaller, repeated injections (e.g., 5-60 mL per run); cumulative dose varies.
Injection Rate	High rate via power injector (e.g., 4-6 mL/s).	Variable, often high-pressure hand or power injections.
Primary Risks	Systemic contrast reaction, PC-AKI, extravasation.	Catheter-related (vessel injury, bleeding, stroke), PC-AKI (higher risk due to first-pass effect and atheroemboli), contrast reaction.
Data compiled from sources:.[4]		

Conclusion and Future Directions

The field of radiologic contrast media has undergone a significant evolution, driven by a continuous effort to maximize diagnostic efficacy while minimizing patient risk. The development of low- and iso-osmolar iodinated agents and stable macrocyclic gadolinium-based agents has dramatically improved the safety profile of contrast-enhanced imaging, leading to direct changes in clinical guidelines and standards of care.

Key safety principles and best practices are paramount. These include meticulous patient screening to identify risk factors such as prior reactions, asthma, and severe renal dysfunction. Risk stratification, primarily through the assessment of eGFR, is essential for guiding decisions regarding the use of contrast and the implementation of prophylactic measures. The choice of agent is critical: modern LOCM or IOCM are the standard for all intravascular iodinated studies, and Group II macrocyclic GBCAs are mandatory for any patient at risk for NSF. Perhaps most importantly, all imaging facilities must maintain a state of readiness to manage acute adverse reactions, with an emphasis on simulation training and immediate access to emergency medications, particularly epinephrine.

Evidence-based guidelines have debunked long-held dogmas, such as the need for routine fasting before IV contrast and the automatic withholding of contrast in patients with moderate renal impairment. Current recommendations for special populations, including pregnant, lactating, and dialysis-dependent patients, and for managing drug interactions like metformin, are nuanced and risk-stratified, allowing for safer and more appropriate use of these vital diagnostic tools.

Future directions in this field will likely focus on several key areas. Ongoing research continues to investigate the clinical significance of long-term gadolinium deposition in the brain and other tissues. The development of novel contrast agents with even better safety profiles, higher efficacy, or tissue-specific targeting remains an active area of pharmaceutical research. Finally, the integration of artificial intelligence into radiology practice holds the promise of optimizing contrast administration by personalizing dosages and injection protocols based on individual patient physiology, potentially further enhancing both image quality and patient safety.

Works cited

1. Contrast Media - 4 Types of Contrast Media and the Best Solutions, accessed October 26, 2025, https://www.wolverson.uk.com/4-types-of-contrast-media-and-the-best-solutions/
2. Radiocontrast agent - Wikipedia, accessed October 26, 2025, https://en.wikipedia.org/wiki/Radiocontrast_agent
3. Radiocontrast Media: Applications and Concerns - PMC, accessed October 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6822330/
4. Contrast Agents (Radiographic Contrast Agents And Iodinated ..., accessed October 26, 2025, https://howradiologyworks.com/contrast-agents-radiographic-contrast-agents-and-iodinated-contrast-media/
5. Contrast Medium: Using Gadolinium or Iodine in Patients with ..., accessed

October 26, 2025, https://www.insideradiology.com.au/contrast-medium-hp/
6. Contrast Media Side Effects: CT vs. MRI Scan Reactions | Tether ..., accessed October 26, 2025, https://www.tethersupervision.com/post/understanding-contrast-media-side-effects-ct-mri-scan-reactions-explained
7. The Essential Role of Barium Sulfate in Medical Imaging - Noah Chemicals, accessed October 26, 2025, https://www.noahchemicals.com/the-essential-role-of-barium-sulfate-in-medical-imaging/
8. pmc.ncbi.nlm.nih.gov, accessed October 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3878741/#:~:text=3.0%20Iodine%2Dbased%20CT%20contrast,choice%20for%20CT%20imaging%20applications.
9. Iodinated contrast media | Radiology Reference Article | Radiopaedia.org, accessed October 26, 2025, https://radiopaedia.org/articles/iodinated-contrast-media-1
10. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms - PMC - PubMed Central, accessed October 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4879157/
11. Gadolinium contrast agents | Radiology Reference Article ..., accessed October 26, 2025, https://radiopaedia.org/articles/gadolinium-contrast-agents
12. Gadolinium Magnetic Resonance Imaging - StatPearls - NCBI Bookshelf - NIH, accessed October 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK482487/
13. Iodinated Contrast Media and Their Adverse Reactions | Journal of Nuclear Medicine Technology, accessed October 26, 2025, https://tech.snmjournals.org/content/36/2/69
14. Toxicity Mechanisms of Gadolinium and Gadolinium-Based Contrast ..., accessed October 26, 2025, https://www.mdpi.com/1422-0067/25/7/4071
15. Contrast agents for X-ray, fluoroscopy, CT and angiography, accessed October 26, 2025, https://www.uclh.nhs.uk/patients-and-visitors/patient-information-pages/contrast-agents-x-ray-fluoroscopy-ct-and-angiography-examinations
16. www.uclh.nhs.uk, accessed October 26, 2025, https://www.uclh.nhs.uk/patients-and-visitors/patient-information-pages/contrast-agents-x-ray-fluoroscopy-ct-and-angiography-examinations#:~:text=In%20x%2Dray%2C%20CT%2C,and%20into%20other%20body%20cavities.
17. MRI contrast agents: Classification and application (Review), accessed October 26, 2025, https://www.spandidos-publications.com/10.3892/ijmm.2016.2744
18. Barium Sulfate: MedlinePlus Drug Information, accessed October 26, 2025, https://medlineplus.gov/druginfo/meds/a606010.html
19. When to Order Contrast-Enhanced CT - AAFP, accessed October 26, 2025, https://www.aafp.org/pubs/afp/issues/2013/0901/p312.html
20. Clinical Pharmacology, Uses, and Adverse Reactions of Iodinated Contrast Agents: A Primer for the Non-radiologist - PubMed Central, accessed October 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3538464/
21. Contrast Media - FV Hospital, accessed October 26, 2025,

https://www.fvhospital.com/learn-more/contrast-media/
22. Iodinated contrast - Wikipedia, accessed October 26, 2025, https://en.wikipedia.org/wiki/Iodinated_contrast
23. ACR Manual on Contrast Media 2024 - Geisel School of Medicine at ..., accessed October 26, 2025, https://geiselmed.dartmouth.edu/radiology/wp-content/uploads/sites/47/2024/08/ACR-contrast-2024.pdf
24. No Fasting Before Intravascular Iodine Contrast Administration ... - NIH, accessed October 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10550736/
25. Intravenous Contrast - StatPearls - NCBI Bookshelf - NIH, accessed October 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557794/
26. MRI with Contrast (Gadolinium-Containing) Policy - UCSF Radiology, accessed October 26, 2025, https://radiology.ucsf.edu/patient-care/patient-safety/contrast/mri-with-contrast-gadolinium-policy
27. Contrast media in patients with kidney disease: An update, accessed October 26, 2025, https://www.ccjm.org/content/87/11/683
28. Barium sulfate contrast medium | Radiology Reference Article | Radiopaedia.org, accessed October 26, 2025, https://radiopaedia.org/articles/barium-sulfate-contrast-medium
29. Contrast Imaging - Applied Radiology, accessed October 26, 2025, https://www.appliedradiology.org/courses/4386%2FPDF%2FBracco_07-21_barium_CE.pdf
30. Barium sulfate (oral route) - Side effects & uses - Mayo Clinic, accessed October 26, 2025, https://www.mayoclinic.org/drugs-supplements/barium-sulfate-oral-route/description/drg-20062255
31. Production of Pulmonary Edema by Aspiration of Water-Soluble Nonabsorbable Contrast Media | Radiology - RSNA Journals, accessed October 26, 2025, https://pubs.rsna.org/doi/10.1148/92.2.367
32. Contrast media adverse reactions | Radiology Reference Article - Radiopaedia.org, accessed October 26, 2025, https://radiopaedia.org/articles/contrast-media-adverse-reactions
33. Management of Severe Allergic-Like Contrast Media Reactions: Pitfalls and Strategies, From the AJR Special Series on Contrast Media, accessed October 26, 2025, https://ajronline.org/doi/10.2214/AJR.23.30044
34. Adverse Reactions to Iodinated Contrast Media - PMC - NIH, accessed October 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3770975/
35. Delayed Adverse Reactions to the Parenteral Administration of Iodinated Contrast Media | AJR - American Journal of Roentgenology, accessed October 26, 2025, https://ajronline.org/doi/10.2214/AJR.13.12310
36. Late adverse reactions to intravascular iodinated contrast media - PubMed, accessed October 26, 2025, https://pubmed.ncbi.nlm.nih.gov/12541128/
37. Delayed Cutaneous Reactions to Iodinated Contrast - MDEdge, accessed October 26, 2025, https://cdn-uat.mdedge.com/files/s3fs-public/Document/June-2018/CT101006433.PDF
38. Iodine-containing contrast medium - InsideRadiology, accessed October 26, 2025, https://www.insideradiology.com.au/iodine-containing-contrast-

medium/
39. Management of Acute Reactions to Contrast Media in Adults - UCSF Radiology, accessed October 26, 2025, https://radiology.ucsf.edu/patient-care/patient-safety/contrast/iodinated/reactions-adults
40. Ask EuroSafe Imaging What Patients Should Know CT Working Group Iodine-Based Contrast Media: Facts and Myths, accessed October 26, 2025, https://www.eurosafeimaging.org/wp/wp-content/uploads/2017/09/201806_CT-WG_TipsTricks_WPSK_final.pdf
41. Guidelines for Contrast Media from the European Society of Urogenital Radiology | AJR, accessed October 26, 2025, https://ajronline.org/doi/10.2214/ajr.181.6.1811463
42. Iodine-containing contrast medium - InsideRadiology, accessed October 26, 2025, https://www.insideradiology.com.au/iodine-containing-contrast-medium-hp/
43. Intravenous iodinated contrast agents: Risks and problematic situations - Cleveland Clinic Journal of Medicine, accessed October 26, 2025, https://www.ccjm.org/content/ccjom/74/5/361.full.pdf
44. Contrast Material for Computed Tomography Scan - Stanford Health Care, accessed October 26, 2025, https://stanfordhealthcare.org/medical-tests/c/ct-scan/procedures/contrast-material.html
45. Management of Contrast Media Reactions - Adult - MD Anderson Cancer Center, accessed October 26, 2025, https://www.mdanderson.org/documents/for-physicians/algorithms/clinical-management/clin-management-contrast-reactions-adult-web-algorithm.pdf
46. Protocol for Management of Patients with Iodine Allergy or Known Allergy to CT IV Radiographic Contrast Media - UCLA Health, accessed October 26, 2025, https://www.uclahealth.org/sites/default/files/documents/Iodine-Allergy-Premedication-Protocol.pdf
47. Management of Severe Allergic-Like Contrast Media Reactions ..., accessed October 26, 2025, https://www.ajronline.org/doi/10.2214/AJR.23.30044
48. Contrast-induced acute kidney injury | Radiology Reference Article | Radiopaedia.org, accessed October 26, 2025, https://radiopaedia.org/articles/contrast-induced-acute-kidney-injury
49. Contrast-Induced Nephropathy - StatPearls - NCBI Bookshelf, accessed October 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK448066/
50. All you need to know about Post Contrast Acute Kidney Injury (AKI) - European Radiology, accessed October 26, 2025, https://www.european-radiology.org/highlights/need-know-post-contrast-acute-kidney-injury-aki/
51. Use of Intravenous Iodinated Contrast Media in Patients with Kidney ..., accessed October 26, 2025, https://pubs.rsna.org/doi/full/10.1148/radiol.2019192094
52. Contrast-Induced Acute Kidney Injury and Cardiovascular Imaging: Danger or Distraction? | Circulation - American Heart Association Journals, accessed October 26, 2025, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062783
53. Post-contrast acute kidney injury – Part 1: Definition, clinical features,

incidence, role of contrast medium and risk factors | springermedizin.de, accessed October 26, 2025, https://www.springermedizin.de/post-contrast-acute-kidney-injury-part-1-definition-clinical-fea/15454744
54. Adverse reactions after intravascular iodinated contrast media administration and their management - Hogrefe eContent, accessed October 26, 2025, https://econtent.hogrefe.com/doi/10.1024/0301-1526/a001122
55. What are the absolute contraindications for Computed Tomography ..., accessed October 26, 2025, https://www.droracle.ai/articles/243553/absolute-contraindications-for-ct-contrast
56. Post-contrast acute kidney injury – Part 1: Definition, clinical features ..., accessed October 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5986826/
57. What are current best practices on holding metformin prior to and post contrast administration? | Drug Information Group | University of Illinois Chicago, accessed October 26, 2025, https://dig.pharmacy.uic.edu/faqs/2023-2/september-2023-faqs/what-are-current-best-practices-on-holding-metformin-prior-to-and-post-contrast-administration/
58. Gadolinium Contrast Medium (MRI Contrast agents) - InsideRadiology, accessed October 26, 2025, https://www.insideradiology.com.au/gadolinium-contrast-medium-hp/
59. Use of MRI/MRA With or Without Gadolinium-Based Contrast Agent (GBCA) for Research, accessed October 26, 2025, https://irb.northwestern.edu/resources-guidance/policies-guidance/guidance-for-use-of-gadolinium-based-contrast-agents-gbcas.html
60. IV Contrast and Hemodialysis – Department of Radiology – UW ..., accessed October 26, 2025, https://radiology.wisc.edu/cr-contrast-and-hemodialysis/
61. Quality Initiatives: Guidelines for Use of Medical Imaging during ..., accessed October 26, 2025, https://pubs.rsna.org/doi/full/10.1148/rg.323115120
62. Imaging Concerns During Pregnancy - Iowa Radiology, accessed October 26, 2025, https://www.iowaradiology.com/imaging-concerns-during-pregnancy/
63. CT and MR Pregnancy Guidelines | UCSF Radiology, accessed October 26, 2025, https://radiology.ucsf.edu/patient-care/patient-safety/ct-mri-pregnancy
64. MRI contrast agent - Wikipedia, accessed October 26, 2025, https://en.wikipedia.org/wiki/MRI_contrast_agent
65. Intravenous contrast agents in diabetic patients taking metformin - Journal of Nephropathology, accessed October 26, 2025, https://nephropathol.com/PDF/jnp-9-e05.pdf
66. Computed Tomography Section Protocol for ... - UCLA Health, accessed October 26, 2025, https://www.uclahealth.org/sites/default/files/documents/Metformin-Protocol.pdf
67. Drug discontinuation before contrast procedures and the effect on ...,

accessed October 26, 2025, https://pubmed.ncbi.nlm.nih.gov/29467030/
68. Preprocedural fasting for contrast-enhanced CT: when experience meets evidence - PMC - PubMed Central, accessed October 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8643287/
69. Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration - American Society of Anesthesiologists (ASA), accessed October 26, 2025, https://www.asahq.org/~/media/sites/asahq/files/public/resources/standards-guidelines/practice-guidelines-for-preoperative-fasting.pdf
70. Aspirated contrast material contributing to respiratory arrest in a pediatric trauma patient., accessed October 26, 2025, https://ajronline.org/doi/pdf/10.2214/ajr.171.2.9694478
71. Rethinking the Routine: Aspiration of Oral Contrast Solution with Bowel Obstruction, accessed October 26, 2025, https://patientsafety.pa.gov/ADVISORIES/Pages/200609_25.aspx
72. Swallowing study using water-soluble contrast agents may increase aspiration sensitivity and antedate oral feeding without respiratory and drug complications: A STROBE-compliant prospective, observational, case-control trial - PubMed, accessed October 26, 2025, https://pubmed.ncbi.nlm.nih.gov/35801762/
73. Cardiothoracic CT Angiography: Current Contrast Medium Delivery Strategies | AJR, accessed October 26, 2025, https://ajronline.org/doi/10.2214/AJR.10.5814
74. Information on Gadolinium-Based Contrast Agents | FDA, accessed October 26, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-gadolinium-based-contrast-agents
75. Gadolinium Contrast Medium (MRI Contrast agents) - InsideRadiology, accessed October 26, 2025, https://www.insideradiology.com.au/gadolinium-contrast-medium/
76. Gadolinium-based Contrast Agents: MedlinePlus Drug Information, accessed October 26, 2025, https://medlineplus.gov/druginfo/meds/a624076.html
77. Does Magnetic Resonance Angiography (MRA) use gadolinium as ..., accessed October 26, 2025, https://www.droracle.ai/articles/351202/does-mra-use-gadolinium
78. Contrast Agents - InsideRadiology, accessed October 26, 2025, https://www.insideradiology.com.au/for-health-professionals/contrast-agents/
79. Differences Between Cardiac CT Scan and Angiogram - Modern Heart and Vascular, accessed October 26, 2025, https://www.modernheartandvascular.com/differences-between-cardiac-ct-scan-and-angiogram/
80. What is the difference in intravenous (IV) contrast media usage for ..., accessed October 26, 2025, https://www.droracle.ai/articles/136639/difference-in-iv-contrast-usage-for-ct-angiogram-vs-conventional-angiogram
81. Management of Patients attending Radiology who are Diabetic or take

Metformin - Newcastle Hospitals NHS Foundation Trust, accessed October 26, 2025, https://www.newcastle-hospitals.nhs.uk/wp-content/uploads/2020/10/Management-of-patients-attending-Radiology-who-are-Diabetic-or-take-Metformin-V1.0-December-2019.pdf
82. CT Angiography Vs. Angiography: What Is Best For You? : Eternal ..., accessed October 26, 2025, https://www.eternalhospital.com/title/ct-angiography-vs-angiography-what-is-best-for-you
83. Differences Between Cardiac CT Scan and Angiogram | Capitol ..., accessed October 26, 2025, https://www.capitolcardiology.com/differences-between-cardiac-ct-scan-and-angiogram